Management of This Complex Obstetric Case

PART 1 - THE MACULOPAPULAR RASH: Diagnosis First

Priority Differential Diagnosis

CRITICAL NOTE - Pemphigoid Gestationis & This Patient's History

Investigations for the Rash

1. VDRL/RPR + TPHA/FTA-ABS - Secondary syphilis must be excluded immediately; it causes a characteristic maculopapular rash on palms and soles, and is treatable with penicillin in pregnancy
2. Rubella IgM + IgG - If seronegative and this is active rubella, fetal anomaly surveillance is needed
3. CBC with differential - Eosinophilia (drug reaction, pemphigoid gestationis)
4. Skin punch biopsy - If diagnosis unclear; direct immunofluorescence can confirm pemphigoid gestationis (C3 at basement membrane zone)
5. HIV screening - If not done
6. Parvovirus B19 IgM/IgG - Can cause maculopapular rash + fetal hydrops
7. LFTs - Obstetric cholestasis (can have rash + systemic features)

Treatment of the Rash (Pending Diagnosis)

PART 2 - NOCTURNAL COUGH WITH WHEEZE (Allergic Asthma at 28 Weeks)

Classification (NAEPP / Creasy & Resnik)

• Nighttime awakening with cough + wheeze = at minimum "Not Well Controlled"
• This maps to Moderate Persistent territory on the severity scale

Step-Care Pharmacotherapy During Pregnancy

1. Salbutamol/Albuterol MDI (SABA) - use as reliever (2 puffs PRN); has the most safety data in pregnancy - Rosen's Emergency Medicine
2. Budesonide inhaled (preferred ICS in pregnancy - Pregnancy Category B, most human data) - 200-400 mcg/day low dose; up to 800 mcg/day medium dose
3. Add formoterol or salmeterol (LABA) if not controlled on medium ICS alone
4. Do NOT stop inhaled corticosteroids - nonadherence is a leading cause of exacerbations; benefits clearly outweigh risks - Creasy & Resnik, p. 1354

Addressing Nocturnal Symptoms Specifically

• Rule out GERD - gastroesophageal reflux commonly exacerbates nocturnal asthma in pregnancy; treat with head-of-bed elevation, avoid food within 3 hours of sleep; add proton pump inhibitor if needed
• Rule out allergic rhinitis/post-nasal drip - intranasal budesonide is safe; use loratadine or cetirizine (second-generation antihistamines; loratadine preferred in 1st trimester though this patient is now in 3rd)
• Trigger avoidance - house dust mites (mattress covers, hot-wash bedding), no tobacco smoke, no strong odors
• PEFR monitoring - establish personal best; green/yellow/red zone action plan; daily monitoring for moderate-persistent asthma

Monitoring in Pregnancy

• Monthly (or more frequent) visits assessing symptom frequency, nocturnal symptoms, albuterol use, spirometry/PEFR
• Fetal surveillance - monthly growth scans (asthma associated with IUGR and preterm birth); antenatal fetal testing in not-well-controlled cases
• Establish accurate gestational age dating (already at 28 weeks)
• Influenza vaccination - recommended for all pregnant asthmatics

Medications to Avoid

• Beta-blockers (even eye drops) - can precipitate bronchospasm
• Aspirin/NSAIDs in aspirin-sensitive patients
• Oral decongestants in first trimester (associated with gastroschisis); prefer intranasal
• Methacholine challenge testing - contraindicated in pregnancy
• Allergy skin testing - generally not recommended due to risk of anaphylaxis

Emergency/Acute Exacerbation Management

• Supplemental O2 to maintain SpO2 >95% (fetal PaO2 dependent on maternal)
• Nebulized salbutamol (2.5-5mg) ± ipratropium
• IV/oral methylprednisolone or hydrocortisone (systemic corticosteroids outweigh risks)
• Avoid intubation if at all possible; involve pulmonologist early

PART 3 - OBSTETRIC CONTEXT (G3P0L0 with GTN History)

• Molar pregnancy surveillance is complete (βhCG negative) - this is important as persistent GTN can recur; the current pregnancy should not be confused with GTN recurrence
• G3P0L0 = two prior pregnancy losses; this patient needs emotional and psychological support alongside medical management
• A multidisciplinary team approach is recommended: obstetrician, pulmonologist/allergist, and dermatologist - Creasy & Resnik, p. 1409
• Uncontrolled asthma in pregnancy is associated with: preterm delivery, low birth weight, pre-eclampsia, and cesarean delivery - prioritize control

Summary Action Plan

Recent Evidence: Asthma in Pregnancy & Rash Differential

PART A - ASTHMA IN PREGNANCY: Current Guidelines & Evidence

1. GINA 2025 (Global Initiative for Asthma - Most Current)

• Asthma control often changes in pregnancy - in ~1/3 of women it worsens, 1/3 improves, 1/3 unchanged
• Do NOT stop ICS before or during pregnancy (Evidence C) - this is the single most common harmful mistake
• ICS + rapid-onset LABA (e.g., budesonide-formoterol) recommended as preferred combination - safe and effective
• Step down should be a low priority until after delivery (Evidence D), given evidence for ICS/LABA safety
• Acute exacerbations in pregnancy must be treated aggressively with SABA + oxygen + early systemic corticosteroids to prevent fetal hypoxia
• During labor/delivery: maintain usual medications; SABA for bronchoconstriction; monitor neonatal blood glucose for 24h if high-dose SABA given within 48h of delivery
• Biologics (if needed for severe asthma): can be used during pregnancy - benefits of controlling severe asthma outweigh theoretical fetal exposure risks

2. Recent Peer-Reviewed Evidence (PubMed)

[Review . 2026] Asthma and Pregnancy: A Narrative Review

• Asthma affects up to 12% of pregnant women globally
• Poorly controlled asthma raises risk of: pre-eclampsia, gestational diabetes, fetal growth restriction, preterm birth, transient tachypnea of the newborn, NICU admission, neonatal seizures, hypoglycemia
• "Factors predicting deterioration in pregnancy: increased severity, suboptimal control, and nonadherence to maintenance therapy" - this patient's pattern (worsening nocturnal symptoms) fits this perfectly
• Physiological changes in pregnancy should NOT worsen FEV1/FVC ratio - any decline warrants investigation
• Most standard treatments including biologics are safe in pregnancy and lactation
• Emphasizes reassuring patients about medication safety as key to improving adherence

[Review . 2025] Asthma in Pregnancy - Clinical Expert Series

• ICS should be a mainstay in ALL pregnant women with asthma - even mild disease
• Recent landmark trials show that as-needed ICS + rapid-onset bronchodilator combination (e.g., budesonide-formoterol) dramatically reduces exacerbations vs SABA-only rescue
• "Clinicians should actively discourage discontinuation or de-escalation of asthma therapies during pregnancy"
• Both chronic asthma and acute exacerbations remain undertreated in pregnancy - a significant clinical gap
• Exacerbations must be treated promptly with systemic corticosteroids + bronchodilators

[Consensus Statement . 2025] Asthma Biologics in Pregnancy

• Consensus: biologics can be initiated/continued throughout pregnancy (including conception and breastfeeding) when clinically indicated
• Shared decision-making with risk vs benefit discussion is recommended
• International registries needed for long-term data

[Review . 2023] Asthma in Pregnancy

• Comprehensive review reaffirming step-care approach, budesonide as preferred ICS, albuterol as rescue therapy

Evidence Table: Asthma Drugs in Pregnancy (Current Consensus)

PART B - PREGNANCY DERMATOSES & RASH DIFFERENTIAL: Current Evidence

[Review . 2022] Recognizing, Diagnosing, and Managing Pregnancy Dermatoses

[Review . 2024] Syphilis Complicating Pregnancy and Congenital Syphilis - NEJM

• Syphilis in pregnancy is a global emergency - cases are rising significantly
• Secondary syphilis: classic maculopapular rash on palms and soles - the distribution matching this patient (hands and legs)
• Untreated syphilis causes stillbirth, fetal death, or congenital syphilis - making early detection vital
• Benzathine penicillin G 2.4 MU IM remains the only proven treatment to prevent congenital transmission
• Screening at first prenatal visit is mandatory; repeat screening at 28 weeks and delivery in high-risk populations - if this patient was not screened at booking, it must be done NOW
• If penicillin-allergic: desensitization and treatment with penicillin is required - no alternative adequately prevents fetal transmission

[Review . 2025] Syphilis: A Review - JAMA

• Updated epidemiology: syphilis incidence is rising globally, including in pregnant women
• Reinforces serologic testing (VDRL/RPR → confirmatory TPHA/FTA-ABS) as essential

Summary: Evidence-Based Action Points for This Case

For the Nocturnal Wheeze/Asthma (based on GINA 2025 + PMID 40472372 + 41015198):

1. Do NOT de-escalate therapy - active step-up is required
2. Prescribe budesonide-formoterol as both maintenance AND as-needed reliever (preferred per GINA 2025)
3. Treat exacerbations aggressively - systemic steroids are safe and necessary
4. PEFR self-monitoring + written action plan
5. Address comorbidities (GERD, rhinitis) as nocturnal triggers

For the Maculopapular Rash on Hands/Legs (based on PMID 38231625 + 36075066):

1. Screen for secondary syphilis urgently - VDRL/RPR at this 28-week visit if not previously done (NEJM 2024 mandates repeat screening at 28 weeks in all women)
2. Rubella IgM/IgG serology
3. If rash is a pregnancy dermatosis: full skin examination, skin biopsy with direct immunofluorescence if bullous or unclear
4. Atopic eruption of pregnancy (AEP) is the only pregnancy-specific dermatosis that can appear in the first trimester - but hand/leg distribution is unusual

Magnesium Sulfate (MgSO4) in Pregnancy with Bronchial Asthma

Short Answer: YES - and it has a dual benefit in this population

Mechanism of Bronchodilation

1. Blocks calcium-mediated smooth muscle contraction - transient blockade of NMDA-gated calcium channels, decreasing intracellular Ca²⁺ in airway smooth muscle
2. Inhibits mast cell degranulation - reducing histamine and bronchoconstrictor mediator release
3. Inhibits acetylcholine release at neuromuscular junctions - reducing cholinergic bronchoconstriction

• Fishman's Pulmonary Diseases and Disorders, p. 274

When to Use MgSO4 in a Pregnant Asthmatic

Indication: Acute Severe / Life-Threatening Asthma NOT responding to first-line treatment

Dosing (Adult, Acute Severe Asthma)

IV MgSO4: 1.2 - 2 g infusion over 20 minutes (single dose)

• Must be given after consultation with senior clinician
• Only after inadequate response to SABA + ipratropium + systemic corticosteroids
• Do NOT repeat - repeated doses risk hypermagnesaemia with muscle weakness and respiratory fatigue

GINA 2025 Recommendation (Most Current)

"In acute care facilities, consider intravenous magnesium sulfate if the patient has an inadequate response to intensive initial treatment."

Dual Role in Obstetrics - The Unique Advantage

"Magnesium sulfate is a bronchodilator" - stated explicitly in the context of labor and delivery management of asthmatic patients.

Special Considerations in This Patient (28 Weeks, Asthmatic)

What to AVOID During Asthma Management in Labor/Delivery

• Creasy & Resnik's Maternal-Fetal Medicine, p. 563

Adverse Effects to Monitor

• Hypotension - especially with rapid infusion (infuse over 20 min, not faster)
• Respiratory depression - at toxic levels (>5 mmol/L serum Mg); keep antidote ready
• Muscle weakness - loss of deep tendon reflexes is an early sign of toxicity
• Cardiac conduction abnormalities - at very high levels
• Neonatal effects - if given close to delivery: neonatal hypermagnesaemia, respiratory depression, hypotonia; monitor neonate

Summary